| Supplementary Protection Certificate (SPC) Summary | |||||||||||||
| SPC No. | 2014/004 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date of filing | 24/01/2014 | ||||||||||||
| Notification of Application Published | 26/02/2014 | ||||||||||||
| Status | Granted | ||||||||||||
| Notification of Grant Published | 01/07/2015 | ||||||||||||
| Date of Expiry of SPC | 03/04/2027 | ||||||||||||
| Applicant |
Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 65926 Frankfurt am Main GERMANY |
||||||||||||
| Patent Number | 1381356 | ||||||||||||
| Title of Invention | USE OF (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID-(4'-TRIFLUOROMETHYLPHENYL)-AMIDE FOR TREATING MULTIPLE SCLEROSIS | ||||||||||||
| Date of Expiry of Patent | 03/04/2022 | ||||||||||||
| Product Type | Medicinal Product | ||||||||||||
| Product Identity | Teriflunomide, its stereoisomer and pharmaceutically acceptable salts thereof | ||||||||||||
| Market Authorisation | Ireland | ||||||||||||
| Authorisation No | EU/1/13/838/001-005 | ||||||||||||
| Authorisation Date | 26/08/2013 | ||||||||||||
| Identity of Product Authorised | AUBAGIO - Teriflunomide | ||||||||||||
| Address for Service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||||||||||||
| Renewal Fees |
|
||||||||||||
| 21/07/2016 | Change of Proprietorship from Aventis Pharmaceuticals Inc, 55 Corporate Drive, Bridgewater, New Jersey 08807, United States of America to Aventisub LLC, 3711 Kennett Pike, Suite 200, Greenville, Delaware 19807, United States of America, by virtue of Certificate of Merger, dated 18/06/2014. | ||||||||||||
| 09/05/2019 | Change of Proprietorship from Aventisub LLC, 3711 Kennett Pike, Suite 200, Greenville, Delaware 19807, United States of America to Sanofi-Aventis Deutschland GmbH, Brüningstrasse 50, 65926 Frankfurt am Main, Germany, by virtue of Deed of Assignment, dated 29/01/2019. | ||||||||||||